Remsima from Celltrion Inc - infliximab biosimilar reshapes IBD therapy costs
23.06.2026 - 05:55:28 | ad-hoc-news.de
Reviewed: ad hoc news New Release & Launch desk. Edited and checked on 2026-06-23, 05:52. Details in the imprint.
Remsima from Celltrion lands in the infusion room as a clear, pale solution dripping steadily through the line while a nurse checks the pump rate. For many patients with Crohn's disease or rheumatoid arthritis, this is the moment joints ease and gut cramps finally quieten.
What Remsima actually is
Remsima is Celltrion's infliximab biosimilar, developed as a monoclonal antibody targeting tumor necrosis factor alpha (TNF-?) for autoimmune diseases including rheumatoid arthritis, Crohn's disease and ulcerative colitis. The official Celltrion product page lists the key indications and TNF-? mechanism. It mirrors the reference drug infliximab (Remicade) in structure, dosage and route of administration under regulatory biosimilarity criteria.
According to Celltrion, Remsima has been approved in over 110 countries, including the EU, UK and multiple markets in Asia and Latin America. A company news release highlights its global approval footprint This broad reach makes it one of the most commercially established anti-TNF biosimilars worldwide.
Background on Celltrion shares
Remsima is a central pillar of the Korean biopharma group's biosimilar strategy and often features in analyses of Celltrion's earnings power and pipeline.
IV, SC and switching in practice
Clinically, Remsima is administered both as an intravenous infusion and, in newer formulations branded as Remsima SC in Europe, as a subcutaneous injection for certain indications. The European Medicines Agency EPAR details these routes and dosing schedules The IV version typically runs over about two hours, with premedication in sensitive patients to reduce infusion reactions.
In everyday use, gastroenterologists like Professor Séverine Vermeire in Leuven, who has spoken publicly about biosimilars, describe switching stable patients from the reference infliximab to Remsima as clinically comparable when monitored properly. Patients often report that the experience in the infusion chair feels no different from their previous brand, apart from the name printed on the drip bag.
Pricing pressure and health budgets
One of Remsima's strongest cards is cost. In Europe, national tenders and hospital contracts have seen infliximab biosimilars, including Remsima, offered at discounts that can reach 30 to 50 percent versus the originator list price, depending on the market and contract terms. Health systems reinvest part of these savings into broader biologic access.
For investors, that pricing dynamic cuts both ways. It capped originator margins but opened substantial volume opportunities for biosimilar players. Celltrion management under chairman Seo Jung-jin has repeatedly framed Remsima as a beachhead product that proves the company's manufacturing scale and regulatory know-how, laying the groundwork for newer antibodies like Truxima and Herzuma.
Where Remsima stands today
From a patient perspective, the biggest practical advantage is simply access. In many hospitals, Remsima is the default infliximab option on the formulary, meaning new patients start directly on the biosimilar instead of the originator. Over time this has normalized biosimilars as routine therapy rather than a second-choice fallback.
There are, however, still careful conversations at the bedside. Some people worry when their biologic is switched for cost reasons, and nurses take time to explain that the molecule, dose and monitoring plan remain the same. When the first post-switch scans show bowel inflammation receding again, those concerns usually soften.
Stock context in one line
Overall, Remsima remains a core revenue driver in Celltrion's portfolio, and Celltrion shares (ISIN KR7068270008) trade on the Korea Exchange in South Korean won, where biosimilar performance is closely watched by institutional holders.
Key data on Remsima
- Product: Remsima (infliximab biosimilar)
- Manufacturer: Celltrion Inc.
- Category: New release/launch biosimilar biologic
- Launch: First EU approval 2013, subsequent launches in additional markets
- RRP / Price: Varies by country and tender; typically discounted versus originator infliximab
- Availability: Hospital and specialist clinics in more than 100 countries, mainly via prescription biologic channels
- Target group: Adults and some pediatric patients with autoimmune conditions such as rheumatoid arthritis, Crohn's disease and ulcerative colitis
- Highlight / USP: Established TNF-? biosimilar offering originator-comparable efficacy with significant health-system cost savings
This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.
